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Running title: Transxylosylation by glucocerebrosidase.  
  










Deficiency of glucocerebrosidase (GBA), a lysosomal β-glucosidase, causes Gaucher disease. The 
enzyme hydrolyzes β-glucosidic substrates and transglucosylates cholesterol to cholesterol-β-
glucoside. Here we show that recombinant human GBA also cleaves β-xylosides and transxylosylates 
cholesterol. The xylosyl-cholesterol formed acts as acceptor for subsequent formation of di-xylosyl-
cholesterol. Common mutant forms of GBA from patients with Gaucher disease with reduced β-
glucosidase activity were similarly impaired in β-xylosidase, transglucosidase and transxylosidase 
activities, except for a slightly reduced xylosidase/glucosidase activity ratio of N370S GBA and a slightly 
reduced transglucosylation/glucosidase activity ratio of D409H GBA. XylChol was found to be reduced 
in spleen from Gaucher disease patients. The origin of newly identified XylChol in mouse and human 
tissues was investigated. Cultured human cells exposed to exogenous β-xylosides generated XylChol 
in a manner dependent on active lysosomal GBA but not the cytosol-facing β-glucosidase GBA2. We 
later sought an endogenous β-xyloside acting as donor in transxylosylation reactions, identifying 
xylosylated ceramide (XylCer) in cells and tissues that serve as donor in the formation of XylChol. UDP-
glucosylceramide synthase (GCS) was unable to synthesize XylChol but could catalyse formation of 
XylCer. Thus, food-derived β-D-xyloside and XylCer are potential donors for the GBA-mediated 
formation of XylChol in cells. The enzyme GCS produces XylCer at a low rate. Our findings point to 
further catalytic versatility of GBA and prompt a systematic exploration of the distribution and role of 
xylosylated lipids. 
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List of abbreviations  
25-NBD-cholesterol: 25-[N-[(7-nitro-2-1,3-benzoxadiazol-4-yl) methyl] amino]-27-norcholesterol 4- 
MU-β-Glc: 4-methylumbelliferyl-β-D-glucose, 4-MU-β-Xyl: 4-Methylumbelliferyl-β-D-xylose, GalCer: 
Galactosylceramide, GBA: β-Glucocerebrosidase, GCS: Glucosylceramide synthase, GD: Gaucher 
Disease, GlcCer: Glucosylceramide, GlcChol: 1-O-cholesteryl-β-D-glucoside, NBD C6- ceramide: (6-((N-
(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)amino)hexanoyl)sphingosine, NPC: Niemann Pick type C disease, 
UDP-Glc: Uridine diphosphate glucose, UDP-Xyl: Uridine diphosphate xylose, XylCer: Xylosylceramide, 
XylChol: 1-O-cholesteryl-β-D-xylose.  
  










The aldopentose, xylose,  resembles the six-membered cyclic pyranose glucose except for lack of the 
pendant CH2OH group. As main building block of xylan, xylose is a major plant sugar (1). In animals, 
uridine diphosphate D-xylose (UDP-Xyl) is used by xylosyltransferases to attach a xylose moiety to 
specific serine or threonine residues in proteoglycans during O-glycosylation (2). Xylose is also found 
in an O-linked trisaccharide repeat in epidermal growth factor and the notch protein as well as the 
blood coagulation factors, F7 and F9. The human body is unable to synthesize the pentose ring of 
xylose de novo but the activated sugar nucleotide UDP-Xyl is obtained from UDP-glucose via UDP-
glucuronate generated by UDP-glucuronic acid decarboxylase 1, which is encoded by the UXS1 gene 
(3).  
Since the first investigations by Fisher & Kent and Patel & Tappel  the structural similarity of xylose to 
glucose and degradation of β-xylosides in animals has been attributed to β-glucosidases (4, 5). We  
observed earlier that indeed the lysosomal acid β-glucosidase GBA, also known as glucocerebrosidase, 
hydrolyzes 4-methylumbelliferyl-β-xyloside (4-MU-β-Xyl) (Aerts, unpublished observation) in contrast 
to the non-lysosomal β-glucosidase GBA2 (6). Inherited defects in GBA cause Gaucher disease (GD), a 
progressive disorder characterized by the accumulation of macrophages loaded with 
glucosylceramide (GlcCer) in tissues (7, 8). No accumulation of β-D-xylose-containing glycopeptides in 
GD patients has been reported, but this possibility has not been formally studied. More recently, 
another catalytic capacity of GBA has been recognized: the transfer of glucose from β-glucoside 
substrates to cholesterol, thus generating glucosyl-β-D-cholesterol (GlcChol) (9-11). Generation of 
GlcChol by GBA is not merely a test-tube phenomenon, but also takes place in vivo (10). In Niemann-
Pick type C disease (NPC), intralysosomal cholesterol is markedly increased owing to genetic defects 
in either of the two proteins, NPC1 or NPC2, that mediate the egress of the sterol from lysosomes 
(12). In this pathological condition, GBA actively generates GlcChol (10). Formation of GlcChol can also 
be induced experimentally by incubating cells with U18666A, an inhibitor of efflux of cholesterol from 









lysosomes. The transglucosylation reaction in cells is prevented by concomitant inhibition of GBA (10). 
The β-glucosidase GBA2, tightly associated to the cytoplasmic leaflet of membranes, also exerts 
transglucosidase activity in vitro and in vivo (10, 13-15).  
The earlier findings on glycon substrate specificity of GBA and the recently noted transglucosidase 
activity of the enzyme, prompted us to examine whether GBA is also able to generate xylosyl-β-D-
cholesterol (XylChol). Here we report on the in vitro xylosylation of cholesterol by GBA, generating  
not only XylChol, but notably also di-xylosyl-cholesterol and even small amounts of tri-
xylosylcholesterol (Xyl2Chol and Xyl3Chol, respectively). Cells and tissues were found to contain low 
concentrations of XylChol. Subsequent investigations indicated that GBA2 plays no role in the 
metabolism (formation of degradation) of xylosylated lipids. Cells when exposed to 4-MU-β-Xyl 
produce XylChol in an entirely GBA-dependent manner. This reaction is favored during intralysosomal 
cholesterol accumulation as induced with the agent U88666A. Formation of XylChol also occurs in cells 
incubated with the plant cyanidin 3-D-xyloside which is found in berries. Our subsequent studies 
revealed the presence of xylosylated ceramide (XylCer) in cells and tissues. This lipid is apparently 
synthesized by glucosylceramide synthase (GCS) using UDP-xylose as sugar donor. The enzyme is 
unable to catalyse formation of XylChol. Our findings on the unexpected existence of xylosylated lipids 
and their metabolism by glucocerebrosidase, are discussed in relation to Gaucher disease.  
  









Materials and Methods  
Materials. 25-[N-[(7-nitro-2-1,3-benzoxadiazol-4-yl)methyl]amino]-27-norcholesterol (25-
NBDcholesterol) and ceramide d18:1/18:1 was purchased from Avanti Polar Lipids (Alabaster, AL, 
USA). (6-((N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)amino)hexanoyl)sphingosine) (NBD C6-Ceramide) 
was purchased from Invitrogen (Waltham, MA, USA). 4-Methylumbelliferyl β-D-glucoside (4-MU-Glc) 
and 4-methylumbelliferyl β-D-xyloside (4-MU-Xyl) were purchased from Glycosynth™ (Winwick Quay 
Warrington, Cheshire, England). Cyanidin-3-O-β-D-xyloside was obtained from Toronto Research 
Chemicals (Martin Ross Ave, North York, Canada). Uridine diphosphate glucose (UDPGlc), cholesterol, 
cholesterol trafficking inhibitor U18666A, 1-O-cholesteryl-β-D-glucose (βcholesteryl glucose, β-
GlcChol) and ammonium formate (LC-MS quality) were from Sigma-Aldrich (St Louis, MO, USA). 
Uridine diphospho-α-D-xylopyranoside (UDP-Xyl) was purchased from CarboSource Services 
(Riverbend Rd, Athens, USA - Supported in part by Grant #DE-FG02- 93ER20097). GBA inhibitor 
Conduritol-β-epoxide (L-1,2-anhydro-myo-inositol; CBE) was purchased from Enzo Life Sciences Inc. 
(Farmingdale, NY, USA), GBA inhibitor ME656 (16) GBA2 inhibitor N-(5-adamantane-1-yl-methoxy-
pentyl)-deoxynojirimycin (AMP-DNM) (17), D-xylo-cyclophellitol, ceramide d17:0/16:0 and 13C6-
GlcChol were synthesized at Leiden Institute of Chemistry (Leiden, The Netherlands) (10, 18, 19). 
Cerezyme®, a recombinant human GBA (rhGBA) was obtained from Genzyme (Genzyme Nederland, 
Naarden, The Netherlands). LC-MS–grade methanol, 2-propanol, water, and HPLC-grade chloroform 
was purchased from Biosolve. XylChol was synthesized as describes in supplemental materials and 
methods.  
Collection of Niemann-Pick type C mouse livers and GD patient spleens. Livers from Npc1-/- mice 
(Npc1nih), along with wild-type littermates (Npc1+/+), were collected in a previous study (10). All human 
spleens were obtained with consent at the Academic Medical Center in Amsterdam following 
therapeutic splenectomy. The phenotype of the subjects was established by clinical examination. All 
organs were stored at -80 °C. Later, homogenates were made from the frozen material in water. 









Cloning and expression of cDNAs encoding GBA2, GBA3 and UGCG (GCS). The design of cloning primers 
was based on NCBI reference sequences NM_020944.2 for human GBA2, and NM_020973.3 for 
human GBA3. HeK293 cell lines were generated with overexpressed GBA2 or GBA3 as described 
previously (10). Glucosylceramide synthase (GCS) in HeLa cells was knocked down by the CRISPR-Cas9 
system (20). For overexpression, the coding sequence of UGCG (GCS) was amplified by PCR (using the 
following oligonucleotides: sense. 5'- 
GGGGACAAGTTTGTACAAAAAAGCAGGCTACCACCATGGCGCTGCTGGACCTG-3'and antisense 5'-
GGGGACCACTTTGTACAAGAAAGCTGGGTCTTATACATCTAGGATTTCCTCTG3’) and cloned into pDNOR-
221 and sub cloned in pcDNA3.1-Zeo via Gateway cloning system (Invitrogen). Correctness of the 
construct was verified by sequencing. HEK293 cells were obtained from the “American Type Culture 
Collection” and cultured in Iscove’s modified Dulbecco’s medium with 5% FBS and 
penicillin/streptomycin under 5% CO2 at 37ºC. For transfection cells were seeded at 75% confluence 
in 6-well plates and transfected using PEI Transfection reagent (Polysciences Inc, Valley Rd, 
Warrington, USA) according to the manufacturer’s instructions, at a PEI:DNA ratio of 3:1. 5  
Culturing and collection of GD fibroblasts. The fundamental research with cell lines was conducted 
with approval by the Ethical Committee of the Academic Medical Centre. Control and GD patient 
fibroblasts homozygous for N370S, L444P and D409H mutations in GBA were cultured in HAMF12-
DMEM medium supplied with 10% FBS and penicillin/streptomycin at 37°C under 7% CO2. Fibroblasts 
cultured from patients with the unique cardiovascular form of Gaucher disease were kindly provided 
by Dr Amparo Chabás (Institut de Bioquimica Clinica, Corporacio Sanitaria, Barcelona, Spain) and by 
Professor Ari Zimran, Sha’are Zedek Hospital Medical Centre, Jerusalem, Israel). Fibroblasts were 
collected by trypsinization followed by 3x washing with ice cold PBS. Cells were homogenized in 25 
mM potassium phosphate buffer pH 6.5 supplemented with 0.1 % (v/v) Triton X-100 by sonication on 
ice.  









In vitro assays with fluorogenic 4-methylumbelliferyl-β-D-glycosides. Enzymatic activity of GBA was 
measured with 3.7 mM 4-MU-β-Glc or 4-MU-β-Xyl, dissolved in 150 mM McIlvaine buffer (pH 5.2 
supplemented with 0.2 % (w/v) sodium taurocholate, 0.1 % (v/v) Triton X-100) and 0.1 % (w/v) BSA) 
(21). The reaction was stopped with NaOH-glycine (pH 10.3), and fluorescence was measured with a 
fluorimeter LS-55 (Perkin-Elmer, Beaconsfield, UK) at λex 366 nm and λem 445 nm. Enzymatic activity 
of GBA2 was measured in lysates of cells overexpressing the enzyme using the same conditions as 
above but without the presence of detergents and at pH 5.8. Enzymatic activity of GBA3 was measured 
in the absence of detergents in 100 mM HEPES buffer at pH 7.0 (22). Stimulation of GBA activity by 
the activator protein saposin C, produced recombinantly in E. coli (23), was monitored with 3.7 mM 
4-MU-β-Glc as substrate in 150 mM McIlvaine buffer pH 4.5 containing 0.1 % (w/v) BSA and 0.4 mg/mL 
phosphatidylserine (24).  
In vitro assay of transglycosidase activity with fluorescent 25-NBD-cholesterol as acceptor. 
Recombinant GBA and lysates of HEK293 cells overexpressing GBA2 and GBA3 were used to determine 
transglycosidase activity of each enzyme. The assays were performed as described earlier (10). First, 
lysates overexpressing GBA2, or GBA3 were pre-incubated with 5 μM CBE for 20 min (samples 
containing diluted recombinant GBA were pre-incubated in the absence of CBE). To each of the 
samples the appropriate buffer containing 4-MU-Xyl or 4-MU-Glc was added for a final donor 
concentration of 3 mM and a final concentration of 40 μM 25-NBD-cholesterol as acceptor. 
Transglycosidase activity of GBA2 overexpressing cells was measured in a 150 mM McIlvaine buffer 
pH 5.8 and the assay for recombinant GBA was done in a 150 mM McIlvaine buffer pH 5.2 containing 
0.1% BSA, 0.1% Triton X-100 and 0.2% sodium taurocholate. For GBA3 the assay contained 100 mM 
HEPES buffer, pH 7.0. The reaction was terminated by addition of chloroform/methanol (1:1, v/v) and 
lipids were extracted according to Bligh and Dyer (25). Thereafter lipids were separated by thin layer 
chromatography on HPTLC silica gel 60 plates (Merck, Darmstadt, Germany) using 
chloroform/methanol (85:15, v/v) as eluent followed by detection of NBD-labelled lipids using a 
Typhoon Variable Mode Imager (GE Healthcare Bio-Science Corp., Piscataway, NJ, USA) (6).  









In vitro assay of GCS activity with fluorescent NBD C6-ceramide as acceptor. HeLa, HeLa GCS KO and 
HeLa GCS KO with overexpression of GCS cells were homogenized in 100 mM potassium phosphate 
buffer pH 7.5 supplemented with 4 mM MgCl2 by sonication on ice. These homogenates were 
incubated with 35 μM NBD C6-ceramide and 10 mM of UDP-Glc or UDP-Xyl for 16 h. Lipids were 
extracted, separated and visualized as described above.  
In vitro assay of transglycosidase activity with cholesterol as acceptor. Assays with natural 
cholesterol or ceramide d18:1/18:1 as acceptor were performed exactly as described in the sections 
above and the subsequent analysis of products was performed by LC-MS/MS as described in the 
section below. In brief for cholesterol: pure rhGBA was incubated at 37˚C with a final concentration 6 
of 32 μM cholesterol and 3.0 mM 4-MU-β-Xyl or 4-MU-β-Glc in 150 mM McIlvaine buffer pH 5.2 
containing 0.1% BSA, 0.1% Triton X-100 and 0.2% sodium taurocholate for the indicated time periods. 
In short for ceramide: 10 mM of UDP-Glc or UDP-Xyl was incubated with 0.16 μM ceramide d18:1/18:1 
for 16 h. All the incubations were stopped by addition of chloroform/methanol (1:1, v/v) and lipids 
were extracted according to Bligh and Dyer (25).  
Assays with cultured RAW264.7 and HEK293 cells. Experiments with cultured RAW264.7 and HEK293 
cells exposed to 3.7 mM 4-MU-β-Xyl or 3.7 mM cyanidin-3-O-β-D-xyloside in the medium, either with 
or without pre-incubation in the presence of U18666A (10 μM), inducing lysosomal cholesterol 
accumulation, were performed as described earlier (10). Lysosomal GBA was irreversibly inhibited by 
prior incubation of cells with 300 μM CBE or 20 nM ME656 (16). Cells were harvested and lipids 
extracted as earlier described (10).  
Synthesis Xylosylated Cholesterol. The synthesis of β-cholesteryl xyloside is described in the 
supplemental materials and methods.  
Generation of XylCer. XylCer was enzymatically generated by incubation of rhGBA with a final 
concentration of 4 μM ceramide d18:1/18:1 and 3.4 mM 4-MU-β-Xyl dissolved in 150 mM McIlvaine 
buffer (pH 5.2 supplemented with 0.2 % (w/v) sodium taurocholate, 0.1 % (v/v) Triton X-100) and 0.1 









% (w/v) BSA) for 16 h at 37 °C. Lipids were extracted according to Bligh and Dyer (25) and dissolved in 
MeOH for HPTLC and LC-MS/MS measurement.  
In vitro assays of glucosylceramide synthase. HeLa cells, HeLa cells overexpressing GCS, HeLa GCS KO 
cells, MEB-4 and GM95 fibroblasts were homogenized in 100 mM potassium phosphate pH 7.5 
containing 4 mM MgCl2. For HPTLC analysis homogenates were incubated with a final concentration 
of 0.2 mM NBD-C6-Ceramide and 20 mM UDP-Glc or UDP-Xyl in 100 mM KpI pH 7.5 containing 4 mM 
MgCl2 for 16 h at 37 °C. For LC-MS/MS analysis cell homogenates were incubated with 35 μM ceramide 
d18:1/18:1 and 20 mM UDP-Glc or UDP-Xyl in 100 mM KpI pH 7.5 containing 4 mM MgCl2 for 16 h at 
37 °C.  
LC-MS/MS analysis. A Waters Xevo-TQS micro instrument was used in all experiments. The instrument 
consisted of an UPLC system combined with a tandem quadruple mass spectrometer as mass analyzer. 
Data were analyzed with Masslynx 4.1 Software (Waters, Milford MA, USA). Tuning conditions for 
GlcChol, XylChol, GlcSph and XylSph in ES+ (electrospray positive) mode are presented in 
Supplemental Table 2. All lipids during this study were separated using an Acquity BEH C18 reversed-
phase column (2.1 x 50 mm, particle size 1.7 μm; Waters). The column temperature and the 
temperature of the auto sampler were kept at 23 °C and 10 °C respectively during the run. The flow 
rate was 0.250 mL/min and volume of injection 10 μL.  
Analysis of GlcChol, and XylChol by LC-MS/MS. For the identification of XylChol, the extracted sample 
was dried and dissolved in methanol. MS parents scan and daughters scan were performed (Figure 
2B). As for GlcChol (10), the most abundant species of XylChol are ammonium adducts, [M+NH4] + 
and the product ion 369.3 represents the cholesterol part of the molecule after loss of the xylose 
moiety. Ammonium adducts of XylChol, Xyl2Chol and Xyl3Chol showed the transitions 536.5>369.3, 
668.5>369.3 and 800.5>369.3 respectively. The transitions for GlcChol are 566.5>369.3 and for 13C6-
GlcChol 572.5>369.3.  









For Multiple Reaction Monitoring (MRM) an isocratic UPLC program was applied during 5.5 minutes 
consisting of 10% eluent A (2-propanol:H2O 90:10 (v/v) containing 10 mM ammonium formate) and 
90% eluent B (methanol containing 10 mM ammonium formate) The divert valve of the mass 
spectrometer was programmed to discard the UPLC effluent before (0 to 0.8 min) and after (4.5 to 5.5 
min) the elution of the analytes to prevent system contamination. The retention time of both GlcChol 
and the internal standard 13C6-GlcChol was 1.36 min. XylChol’s were either synthesized or generated 
in vitro by incubation of GBA with 4-MU-β-Xyl and cholesterol. The retention time of XylChol, Xyl2Chol 
and Xyl3Chol was 1.71 min, 1.49 min and 1.40 min respectively (Supplemental Figure 1). Lastly, 50 μL 
plasma was spiked with pure XylChol (concentrations: 0, 0.5, 1, 2.5, 5, 10, 25, 50, 100, 200, 500, 1000 
pmol XylChol/mL of plasma), internal standard 13C6-GlcChol was added and samples were extracted. 
A linear response was obtained over the entire concentration range (y= 0.0108x + 1.9888, R2 = 0.998). 
The area from transition XylChol over the area from the transition of internal standard (the ratio) was 
plotted against the concentration of XylChol in the plasma samples. The limit of detection was 0.5 
pmol/mL plasma with a signal-to-noise ratio of three and the limit of quantification was 1.6 pmol/mL 
plasma with a signal-to-noise ratio of ten. Calculation of the signal-to noise ratio was done using the 
peak-to-peak method.  
LC-MS/MS quantification of GlcChol and XylChol produced in vitro. Following incubation of rhGBA 
and cholesterol with either 4-MU-β-Glc or 4-MU-β-Xyl, lipids were extracted according to the method 
of Bligh and Dyer by addition of methanol, chloroform and water (1:1:0.9, v/v/v). The lower phase was 
taken to dryness in an Eppendorf concentrator. Isolated lipids were purified by water/butanol 
extraction (1:1, v/v). The upper phase (butanol phase) was dried and dissolved in methanol, sonicated 
in a bath sonicator and samples were analyzed by LC-MS.  
LC-MS/MS quantification of GlcChol and XylChol’s in cultured cells and organs. Cells were 
homogenized in 25 mM potassium phosphate buffer pH 6.5 containing 0.1% (v/v) triton, by sonication 
on ice. Livers and spleens were homogenized in water. Prior to extraction, 13C-labelled GlcChol and 









ceramide d17:0/16:0 in methanol (both used as an internal standard) were added to the homogenate. 
Samples were then treated with methanol:chloroform (1:1, v/v) to precipitate the proteins, following 
further extraction of the supernatant as described above.  
Analysis of GlcCer, and XylCer by LC-MS/MS. To measure GlcCer and XylCer, lipids were deacylated 
(26) after Bligh and Dyer extraction with methanol, chloroform and 100 mM formate buffer pH 3.1 
(1:1:0.9, v/v/v). Next, sample was evaporated and purified by water/butanol extraction (1:1, v/v). The 
butanol phase was dried, the final sample dissolved in methanol and GlcSph and XylSph levels 
measured. GlcSph was analyzed as published previously (19, 27). For XylSph identification the sample 
was introduced in the mass spectrometer using LC-MS/MS (from 0 to 6.5 min to the detector), using 
eluent A (H2O:formic acid 99.5/0.5 (v/v) containing 1 mM ammonium formate) and eluent B 
(methanol:formic acid 99.5/0.5 (v/v) containing 1 mM ammonium formate). A mobile phase gradient 
was used during the run: 0.00 min 0% B, 2.50 min 100% B, 6.00 min 100% B, 6.05 min 0% B and 6.50 
min 0% B. MS parents scan and daughters scan were performed (Supplemental figure 2). The MRM of 
precursor > fragment ions (m/z GlcSph 462.3 > 282.3and XylSph 432.7 > 282.3) was used for 
quantification.  
Docking. PDB 2V3D was obtained from the PDB database and the N-butyl-deoxynojirimycin ligand was 
removed. XylChol was made with JLigand (28) and manually docked using COOT (29). Inhibitor 8 crystal 
structures of PDB 2V3D, 2XWE and 6Q6L were used as reference structures during docking (16, 30, 
31). Final figures were made using CCP4MG (32).  
Protein determination. Protein was measured with the Pierce BCA Protein Assay kit (Thermo 
Scientific). Absorbance was measured in EL808 Ultra Microplate Reader (BIO-TEK Instruments Inc.) at 
562 nm.  
Statistical Analysis. Values in figures are presented as a mean ± S.D. Data were analyzed by unpaired 
Student’s t-test or Mann-Whitney U-test. P values < 0.05 were considered significant. * P < 0.05, ** P 
< 0.01 and *** p < 0.001.  










Cleavage of 4-methylumbelliferyl-β-D-xylose by GBA.  
We first compared the ability of pure rhGBA to cleave 4-MU-β-Xyl and 4-MU-β-Glc. The enzyme 
releases fluorescent 4-MU from both substrates, but the noted activity towards 4-MU-β-Xyl is around 
50-fold lower as the result of a higher Km and lower Vmax (Figure 1A insert, Supplemental Table S1). The 
activity of GBA towards both substrates shows a similar pH optimum (Figure 1A) and taurocholate 
stimulation (Figure 1B). The stimulatory effect of recombinantly produced saposin C on GBA-mediated 
cleavage of 4-MU-β-Glc and 4-MU-β-Xyl is also comparable (Figure 1C). The kcat/Km of recombinant 
GBA is about 40-fold higher for 4-MU-β-Glc than 4-MU-β-Xyl (Table S1). The retaining β-glucosidase 
GBA employs the Koshland double displacement mechanism for catalysis with E340 as nucleophile 
and E325 as acid/base (33). Blocking glutamate E340 by covalent inhibition of cyclophellitol (CP) 
abolishes the activity of GBA (34). Of note, the activity of GBA towards 4-MU-β-Glc and 4-MU-βXyl 
substrates was found to be quite comparably inhibited during pre-incubation with cyclophellitol for 
90 minutes. The slightly higher apparent IC50 observed with 4-MU-β-Glc (85 nM) than with 4- MU-β-
Xyl (61 nM) is likely explained by the greater protection by the β-D-glucose substrate against 
irreversible inhibition of GBA. Recently a xylose analogue of cyclophellitol was synthesized (18). It was 
observed that GBA is also irreversibly inactivated by D-xylo-cyclophellitol, although with lower affinity 
than cyclophellitol (Supplemental Table S1). Again, the apparent IC50 determined with 4-MUβ-Glc 
(10.2 μM) is slightly higher than with 4-MU-β-Xyl substrate (6.4 μM), presumably due to better 
protection of GBA against irreversible inhibition by the presence of 4-MU-β-Glc.  
 
Transxylosylation activity of GBA.  
We investigated rhGBA with respect to transxylosylation activity. For this, rhGBA was incubated for 16 
h with 4-MU-β-Glc or 4-MU-β-Xyl as donor and fluorescent 25-NBD-cholesterol as acceptor, and the 
resulting products were analyzed by HPTLC and fluorescence scanning. Formation of fluorescent sterol 









metabolites occurred with both donors (Figure 2A). With 4-MU-β-Glc, glucosylated 25-NBD-
cholesterol is formed as earlier described (10). With 4-MU-β-Xyl, two novel fluorescent metabolites 
were detected, presumed to be mono- and di-xylosylated 25-NBD-cholesterol (Figure 2A). Next, we 
used natural cholesterol as acceptor and 4-MU-β-Xyl as donor. After incubation with rhGBA with pure 
4MU-β-Xyl, the formed products were analyzed by LC-MS/MS. Formation of XylChol, Xyl2Chol, and 
traces of Xyl3Chol was detected (Figure 2B). Apparently, sequential transxylosylation can occur. In 
sharp contrast, incubation of GBA and cholesterol with 4-MU-β-Glc only renders GlcChol as product 
(Figure 2C) (10).  
 
Time-dependence of glycosidase and transglycosidase activities of GBA.  
GBA and cholesterol were incubated with 4-MU-β-Glc or 4-MU-β-Xyl at 37 ˚C for different time 
periods. The release of 4-MU and formation of glycosylated products was determined. The formed 
GlcChol was already maximal after 30 min and subsequently declined with time (Figure 2C). 
Apparently, the formed GlcChol is subject to subsequent hydrolysis by GBA. In sharp contrast, XylChol 
showed no prominent reduction over time, and Xyl2Chol was formed after a lag period (Figure 2D). 
This suggests that XylChol is hardly hydrolyzed and acts as acceptor for further xylosylation. This 
process continues with Xyl2Chol acting as acceptor rendering Xyl3Chol (Figure 2D). A comparison of 
the release of 4-MU with concomitant formation of glycosylated sterol indicates that GBA shows 




In vivo formation of xylosylated cholesterol.  
To substantiate our in vitro findings, potential transxylosylation by cultured RAW264.7 cells exposed 
to 3.7 mM 4-MU-β-Xyl was investigated. Cells were incubated with or without the irreversible GBA 
inhibitor conduritol B-epoxide (CBE) either in the absence (Figure 3A) or presence of 10 μM U18666A 









(Figure 3B) to induce lysosomal accumulation of cholesterol (10). Formation of XylChol, Xyl2Chol and 
Xyl3Chol was detected by LC-MS/MS. The levels of xylosylated cholesterols were markedly increased 
by the exposure of cells to U18666A and formation was prohibited by prior inhibition of GBA with CBE 
(Figure 3A and 3B).  
Several β-xylosidic compounds are known to be produced by plants and these compounds are likely 
to be assimilated after ingestion in   food (35, 36). We therefore investigated whether cyanidin-3-O-
β-D-xyloside from berries (see supplemental Figure S3 for chemical structure) can act as sugar donor 
in cellular formation of XylChol. For this purpose, RAW264.7 cells were incubated with cyanidin-3-O-
β-D-xyloside for 24 h and the formation of XylChol was monitored. Indeed, xylosylated cholesterol was 
formed by the RAW264.7 cells in GBA-dependent manner, as indicated by the inhibitory effect of GBA 
inactivation with the specific irreversible inhibitor ME656 (Figure 3C, see supplemental Figure S3 for 
ME656 chemical structure). We next investigated the possible involvement of the enzyme 
glucosylceramide synthase (GCS) (37, 38). No involvement of GCS in the synthesis of XylChol was 
detected with an in vitro GCS assay (Figure 3D). Furthermore,  HeLa cells in which GCS was inactivated 
by CRISPR-Cas9 were found to produce XylChol on a par with  corresponding normal cells when 
exposed to 4-MU-β-Xyl and U18666A (Figure 3E).  
 
Specificity of transxylosylation.  
We next studied the transxylosylation ability of two other human retaining β-glucosidases, GBA2 and 
GBA3. We earlier noticed that GBA2, but not GBA3, mediates transfer of the glucosyl moiety from 4- 
MU-β-D-Glc to cholesterol or ceramide (10). While this finding was recapitulated (Supplemental Figure 
S4), concomitantly no xylosylation by GBA2 was detectable. This finding is consistent with the noted 
inability of GBA2 to hydrolyze 4-MU-β-Xyl (6). In contrast, GBA3, albeit less prominent than GBA, was 
found to be able to hydrolyze 4-MU-β-Xyl as well as to transxylosylate cholesterol (Supplemental 
Figure S4).  
 









β-Xylosidase and transxylosylation activities of mutant glucocerebrosidase of GD patients.  
Mutant forms of GBA commonly encountered in GD patients were studied regarding catalytic 
features. As source of GBA enzymes, lysates of control and GD patient fibroblasts homozygous for 
N370S, L444P and D409H mutations in GBA were used. Cell lysates were incubated with either 4- MU-
Glc or 4-MU-Xyl to determine their glucosidase and xylosidase activity by measuring the 4-MU release. 
Lysates were also incubated with 4-MU-Glc and 4-MU-Xyl concurrently with cholesterol as acceptor, 
followed by GlcChol and XylChol measurement (Table 1). Of note, we related various activities to β-
glucosidase activity. It should be kept in mind that in lysates of GD patient fibroblasts the absolute β-
glucosidase activity is reduced compared with lysates of fibroblasts from healthy individuals. In the 
case of most patient fibroblast lysates the β-glucosidase and β-xylosidase were reduced 
commensurately, thus the mutant enzyme showed no preference for one or other substrate. Likewise, 
transglucosidase and transxylosidase activity levels in patient lysates were changed in proportion to 
their β-glucosidase activity. However, in the case of N370S GBA, there was a subtle decrease in the 
xylosidase/glucosidase ratio compared with the control enzyme.. Additionally, we  consistently 
observed a reduced transglucosylation/glucosidase activity in GD fibroblasts with a D409H mutation 
in GBA compared with control cells. This was noted with multiple patient cell lines. Similar 
observations were made with mutant GBA enzymes expressed in HEK293T cells lacking endogenous 
GBA following CRISPR-Cas9 mediated gene disruption, and GBA expressed in GD fibroblasts with 
virtually no endogenous GBA (data not shown). Thus, only minor abnormalities in the various catalytic 
activities of mutant GBA enzymes were noted.  
 
Natural occurrence of xylosylated cholesterol.  
Next, the occurrence of XylChol in cells and tissues was investigated. Synthesized XylChol was used as 
standard in LC-MS/MS quantification. Figure 4A shows the XylChol detection in lysates of 11 
fibroblasts and HeLa, HEK293T and RAW264.7 cells as well as in human spleen and mouse liver. The 
XylChol levels are relatively low as compared to those of HexChol (GlcChol and/or GalChol). In cells, 









XylChol levels are on average 130-fold lower than those of HexChol. In liver, relatively low amounts of 
XylChol were noted, but considerable XylChol levels were detected in liver of Npc1-/- mice. The Npc1-
/- liver was earlier found to also contain high concentrations of GlcChol (10). Of note, reduced XylChol 
concentrations were observed in spleens of type 1 GD patients.  
 
Xylosylated ceramide as a potential xylose donor for GBA.  
In our search for the endogenous xylose donor in the generation of XylChol, we investigated the 
possible occurrence of xylosylated ceramide (XylCer). For this purpose, a LC-MS/MS based 
quantitation, based on microwave-assisted deacylation of XylCer to xylosylated sphingosine, was 
developed. We measured XylCer levels in the same materials previously used for XylChol 
measurements (Figure 4B). The study revealed that XylCer is increased in GD spleen, whereas XylChol 
is reduced in the same tissue (Figure 4A). Apparently, GBA does not degrade XylChol but rather 
synthesises it. On the other hand, GBA can degrade XylCer. The observed increased levels of XylCer in 
NPC mouse liver can be likely ascribed to the secondary deficiency of GBA in this organ (10).  
To test whether XylCer is a suitable sugar donor in GBA-mediated formation of XylChol, we 
enzymatically generated XylCer and then incubated it with 32 μM cholesterol and rhGBA. Abundant 
formation of XylChol was detected by LC-MS/MS (Figure 5A), confirming that XylCer may act as a sugar 
donor in XylChol formation.  
 
Glucosylceramide synthase synthesizing xylosylated ceramide.  
Our discovery of XylCer stimulated a subsequent search for the XylCer generating enzyme. As 
candidate, the enzyme GCS was tested. An in vitro assay with lysate of HEK293T cells incubated with 
UDP-Xyl as donor and NBD C6-ceramide as acceptor, led to formation NBD-XylCer and some 
NBDXyl2Cer (Figure 5B). The same assay performed with ceramide d18:1/18:1 as acceptor resulted in 
formation of XylCer as detected by LC-MS/MS (Figure 5C). Lysates of cells lacking GCS were unable to 
generate XylCer. Expression of GCS in the GCS KO cells, reinstalled their ability to produce XylCer 









(Figure 5C). The ability of GCS to synthesise XylCer was further confirmed using lysates of the GCS-
deficient GM95 cells and the parental GCS-competent MEB4 B16 cells incubated with UDP-Xyl and 
ceramide d18:1/18:1, where only the MEB4 cells showed formation of XylCer (Figure 5D).  
  











Here we report investigations into an intriguing catalytic feature of the lysosomal 
glucocerebrosidase, GBA. We noted first that beyond 4-MU-β-Glc, GBA also cleaves the substrate 4- 
MU-β-Xyl. Moreover, the enzyme uses both substrates as sugar donors in transglycosylation reactions 
with cholesterol as acceptor. Next, we detected the generation of xylosylated cholesterol in living cells 
exposed to 4-MU-β-Xyl. Induction of lysosomal cholesterol accumulation in cells with U18666A 
increased formation of xylosylated cholesterols, a reaction prevented by inactivation of GBA with the 
irreversible inhibitors CBE or ME656 (16). Of special note, GBA even produces di-xylosyl-cholesterol 
using 4-MU-β-Xyl as sugar donor in vivo as well as in vitro: this repetitive transglucosylation is not 
observed when 4-MU-β-Glc is used as sugar donor (10).  
 
The affinity of GBA for 4-MU-β-Glc as substrate for hydrolysis exceeds that for 4-MU-β-Xyl. 
Likewise, XylChol is a much poorer substrate for hydrolysis by GBA than GlcChol. Following exposure 
of GBA to cholesterol and 4-MU-β-Xyl, the concentration of XylChol steadily builds up and it acts as 
acceptor in a second round of transxylosylation, rendering Xyl2Chol. Incubation of GBA and cholesterol 
with a mixture of 4-MU-β-Xyl and 4-MU-β-Glc leads to formation of GlcXylChol (supplemental Table 
S3), further highlighting the suitability of XylChol as acceptor in transglycosylation by GBA. Of note, 
Aerts and co-workers earlier noted also relative higher net transxylosylation than transglucosylation 
efficiency of a β-D-glucosidase from Stachybotrys atra (37), quite comparable to our findings with 
GBA. We docked GlcChol and XylChol in the crystal structure of human GBA. It appears that the CH2OH 
group in combination with N396 guides the substrate in an orientation which is optimal for hydrolysis. 
The lack of interaction between the CH2OH group and N396, as is the case with XylChol, probably 
results in a different orientation of the glycan moiety and hence affects the orientation and availability 
of the glucosidic bond for hydrolysis (Supplemental Figure S5). Obviously, crystallographic studies with 
soaked lipids in GBA crystals will be required to obtain conclusive data and further insight. Of note, 









Akiyama et al. recently reported that GBA is able to generate at low rate galactosylated cholesterol 
(GalChol) from galactosylceramide and cholesterol (39). The enzyme however hardly hydrolyzes β-
galactosides, including GalChol.  
 
The possible physiological relevance of the observed transxylosylation by GBA warrants 
discussion. Using mass spectrometry, the presence of significant amounts of XylChol in liver of Npc1- 
/- mice could be demonstrated. XylChol was also detected in low quantities in cells, liver and spleen. 
Interestingly, in type 1 GD spleens XylChol levels were clearly reduced as compared to control spleens. 
This finding substantiates the notion that GBA is largely responsible for formation of XylChol and 
poorly degrades it. In contrast, the enzyme hydrolyzes 4-MU-β-xyloside and GlcChol relatively much 
better.  
 
The cytosol-facing membrane-bound β-glucosidase GBA2, shown earlier to potently 
transglucosylase cholesterol to generate GlcChol, has in contrast no significant activity towards β-
xyloside substrates. Apparently the pendant CH2OH group in glucoside substrates contributes crucially 
to the interaction of substrate with GBA2. The importance of the presence of the additional CH2OH 
group in glucose also correlates with the much lower affinity of GBA2 for the inhibitor conduritol-B 
epoxide (with C5-hydroxymethyl group) compared with  cyclophellitol (with C5-CH2OH group) (40). 
(34). The enzyme GBA2 also hydrolyses β-galactosides and is able to generate GalChol via 
transgalactosylation (6, 39). In contrast to GBA2, the enzyme GBA3, a cytosolic broad-specificity 
glucosidase implicated in metabolism of xenophobic glycosides (22), shows xylosidase and 
transxylosidase activity in vitro. The contribution of this enzyme in metabolism of xylosides in tissues 
remains  unclear.  
 
Our discovery of several catalytic activities of GBA (i.e., β-glucosidase, β-xylosidase, 
transglucosylase and transxylosylase activity) prompted us to explore the possibility that specific 









mutant forms of GBA that occur in patients with Gaucher disease may have selective abnormalities in 
one of these activities. Numerous amino acid substitutions in GBA are  responsible for Gaucher disease 
and several are sufficiently well-characterized in their association with the clinical severity or 
phenotype in affected patients. For example, the heteroallelic presence of N370S GBA is protective 
for a neurological disease course  in children and young adults, although it may be associated with 
Parkinsonism and dementia in later life (41). Analysing patient fibroblasts that harbour the common 
mutations N370S, L444P or the apparently unique D409H mutation in GBA that is associated with a 
unique clinical syndrome of cardiovascular disease, did not indicate gross abnormalities in any of the 
catalytic activities, as tested with 4MU-Glc and 4-MU-Xyl as substrates and cholesterol as acceptor.  
 
We were particularly interested in any abnormalities in catalytic features of D409H GBA, since 
this mutation, when present in in homozygous form, is associated with extraordinary and unique 
clinical manifestations. The phenotype includes a chronic neurological phenotype with oculomotor 
apraxia and low-pressure hydrocephalus as well as the unusual feature of opacification of the cornea. 
However, the most striking feature in D409H homozygotes is Gaucher cell infiltration of the proximal 
aorta with calcification that involves the coronary arteries and left-sided cardiac valves (42-44). We 
observed a slightly reduced transglucosylase/glucosidase ratio for D409H GBA. While the molecular 
basis of this phenotype remains unknown, we contend that careful study of the affected tissues 
obtained from patients who are affected for the presence of glucosylated metabolites offers perhaps 
the best opportunity for definitively solving the pathophysiology. The possibility that additional 
metabolites besides cholesterol are glucosylated via transglucosylation reactions is  under active 
investigation.  
 
In the course of our investigation a key question concerned the nature of physiological 
xyloside donors explaining the presence of XylChol. Several β-xylosidic compounds are known to be 
produced by plants and their uptake via food can “a priori not” be excluded (37, 38). Indeed, we did 









observe formation of XylChol in cells when incubated with cyanidin-3-O-β-D-xyloside, a ubiquitous 
compound in plums and berries. Thus, plant derived β-xylosides might act as suitable donors for GBA-
mediated formation of xylosylated sterols but the quantitative importance of such reaction with an 
exogenous sugar donor is yet unclear. Theoretically, an alternative endogenous donor of β-D-xylosyl 
moieties might be β-D-xylosyl-peptides formed during the lysosomal degradation of proteoglycans.  
 
Our investigation did reveal another, somewhat unexpected, endogenous β-xyloside: 
xylosylated ceramide. This unusual molecule has been previously reported to occur in  the salt gland 
of the herring gull (45). We detected XylCer by mass spectrometry in various human and mouse tissues  
although at very low concentrations compared with GlcCer; we moreover showed  that XylCer serves 
as a sugar donor in the transxylosylation of cholesterol by GBA. Next, we observed that GCS is able to 
use UDP-Xyl to form XylCer, although with much lower affinity than UDP-Glc. XylCer was found to be 
elevated in the  spleen of patients with Gaucher disease – a finding consistent with a role as a substrate 
for GBA and a sugar donor in transxylosylation mediated by the lysosomal enzyme.  However, at the 
time of writing, the physiological relevance of the relatively minute  amounts of XylCer is  unclear and 
merits further investigation. Further investigation will also be required  to establish to what extent 
exogenous β-xylosides of plant origin or endogenous β-xylosides (β-D-xylosyl-peptides or XylCer) serve  
as donors in the formation of XylChol. 
 
Our findings regarding xylosylated lipids are summarized in the scheme. We observed that 
ceramide can be modified by the enzyme GCS to xylosyl-ceramide. This, or an exogenous β-xyloside, 
can act as donor in the formation of xylosyl-cholesterol by the enzyme GBA via a transglucosylation 
reaction. The formed xylosyl-cholesterol is poorly degraded and may act in the presence of large 
amounts of β-xyloside as acceptor in the further addition of xylosyl-moieties by GBA. The linkage of 
the subsequent xylosyl moieties is likely β-1,4, but β-1,2 or β-1,3 linkage cannot be excluded.  
 










In conclusion, human GBA is more versatile in catalysis than hitherto considered. Investigation of the 
(patho)physiological relevance of various reactions catalyzed by GBA and xylosylated lipids is urgently 
needed to complete our understanding of the pathogenesis of Gaucher disease (7, 8) and other 
conditions for which abnormal GBA imposes a risk, such as multiple myeloma and α-synucleinopathies 
like Parkinsonism and Lewy-body dementia (46, 47).  
 
Data Availability Statement  
All the data are stored at the Department of Medical Biochemistry, Leiden University (The 
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Footnote 
The initial observation regarding beta-xylosidase and transxylosylation activity of human 
glucocerebrosidase is reported in chapter 16 of the thesis Glycosphingolipidosis by Maria Ferraz 
(University of Amsterdam; https://dare.uva.nl/search?identifier=6df4fcae-33df-4e73-917c-
145267cb98f8). It triggered the further detailed investigations on the phenomenon and the discovery 
of the role of glucosylceramide synthase in endogenous formation of xylosylated lipids. 
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Table 1. Catalytic features of mutant GBA enzymes.  
Relative enzymatic activities in fibroblasts lysates from GD patients incubated with 4-MU-Glc or 4-MU-
Xyl to determine glucosidase and xylosidase activity, and values are expressed ± SD. Assays were 











Ctrl  0.035 ± 0.007 0.654 ± 0.076 0.044 ± 0.006 1.248 ± 0.157 
N370S  0.018 ± 0.001 0.391 ± 0.081 0.029 ± 0.012 1.615 ± 0.652 
L444P 0.028 ± 0.000 0.571 ± 0.066 0.044 ± 0.004 1.557 ± 0.149 
D409H  0.028 ± 0.004   0.182 ± 0.071*   0.030 ± 0.001 1.057 ± 0.038 
 
  









Figures & Legends to figures 
 




Figure 1: Cleavage of 4-MU-β-Glc and 4-MU-β-Xyl by recombinant human rhGBA.  
A. pH optimum of 4-MU release by GBA from 4-MU-β-Glc (closed circles) and 4-MU-β-Xyl (open 
circles). Insert: specific activity of rhGBA with 4-MU-β-Glc and 4-MU-β-Xyl. B. Stimulation by 0.2 % 
(w/v) taurocholate of 4-MU release from the substrates 4-MU-β-Glc (left) and 4-MU-β-Xyl (right) at 
pH 5.2 in the presence of 0.1% (v/v) Triton X-100 and 0,1 % bovine serum albumin. Expressed as 100% 
is the activity in the absence of taurocholate. C. Stimulation of 4-MU release from the substrates 4-
MU-β-Glc (left axis) and 4-MU-β-Xyl (right axis) by recombinant saposin C at pH 4.5 in the presence of 

















Figure 2: Transxylosylation and transglucosylation of cholesterol by GBA.  
A. HPTLC analysis of fluorescent products formed from 25-NBD-cholesterol following incubation with 
rhGBA in the presence of 4-MU-β-Glc or 4-MU-β-Xyl for 16 h. B. LC-MS/MS analysis of products formed 
after 1 h incubation of rhGBA, cholesterol and 4-MU-β-Xyl. C. Release of 4-MU from 4-MU-β-Glc and 
concomitant formation of glucosylated cholesterol in time. D. Release of 4-MU from 4-MU-β-Xyl and 
concomitant formation of xylosylated cholesterol in time. rhGBA was incubated at pH 5.2 in the 
presence of taurocholate and Triton X-100 with 3.7 mM 4-MU-substrates for indicated times. (n = 2, 


















Figure 3: Formation of xylosylated cholesterols.  
A. LC-MS/MS detection of formed XylChol and HexChol (GlcChol or GalChol) in RAW264.7 cells 
incubated with 3.7 mM 4-MU-β-Xyl for 24 h in the presence/absence of CBE, n = 3 technical replicates 
± SD. B. Experiment A in the presence of 10 μM U18666A. C. LC-MS/MS detection of formed 
xylosylated cholesterol in RAW264.7 cells incubated with 3.7 mM cyanidin-3-O-β-D-xyloside for 24 h 
in the presence/absence of U18666A with or without GBA inhibitor ME656, n = 2 technical replicates 
± SD. D. HPTLC of in vitro formation of xylosylated cholesterols by HeLa cell lysate using NBDChol as 
acceptor and 4-MU-Glc, 4-MU-Xyl, UDP-Glc and UDP-Xyl as (potential) sugar donors in the 
presence/absence of GCS inhibitor Eligustat. E. LC-MS/MS detection of formed xylosylated and 
glucosylated cholesterols in HEK293 and HEK293 GCS KO cells exposed to 3.7 mM 4-MU-β-Xyl and 
U18666A for 24 h, n = 3 technical replicates ± SD. *= p < 0.05; **= p < 0.01; ***= p < 0.001. 
  












Figure 4: Levels of xylosylated cholesterol and xylosylated ceramide found in cells and organs.  
A. LC-MS/MS analysis of XylChol (A) and XylCer (B) occurrence in Fibroblasts, HeLa, HEK293, RAW264.7 
cells human control spleens, human GD spleens, mouse control livers and mouse Npc1-/- livers (n =2 
technical duplicates ± SD). 
 
  












Figure 5: XylCer acts as a donor for GBA to transxylosylate cholesterol and can be synthesized by 
GCS. A. XylCer (formed by incubation of 4-MU-Xyl, Ceramide d18:1/18:1 and rhGBA at pH 5.2) was 
incubated with rhGBA and cholesterol at pH 5.2 for 18 h at 37°C. The figure depicts LC-MS/MS 
measurement of formed XylChol. Error bars represent standard deviation of technical duplicate. B. 
HPTLC analysis of formation of glycosylated NBD C6-ceramide by GCS with 0.2 mM NBD C6- ceramide 
and 20 mM UDP-Glc or UDP-Xyl as donor. C. LC-MS/MS analysis of formed xylosylated ceramide after 
16 h incubation of cell lysates of control HeLa, HeLa GCS KO or HeLa GCS KO with a reintegrated 









overexpression of GCS with UDP-Xyl and ceramide d18:1/18:1 (n = 2, mean ± SD). D. LC-MS/MS 
analysis of formed glycosylated ceramide after 16 h incubation of mouse fibroblast lysates with UDP-
Xyl and ceramide d18:1/18:1 (n = 2, mean ± SD). 
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